

AGENDA FOR THE ACCELERATE ANNUAL CONFERENCE

Shifting Gears in Paediatric Cancer Innovation

'The Dual engine approach': To cure more children and adolescents with cancer, we must both accelerate the smart development and use of adult cancer innovations and build new paediatric-first development pathways to incentivize the development of specific paediatric oncology drugs.

DAY 1 – 5th FEB

09:00 – 10:00	Welcome Coffee
10:00 - 10:20	Introduction <ul style="list-style-type: none"> Vision and Mission of ACCELERATE - <i>Nicole Scobie, ACCELERATE</i> Goals of the Conference - The Thread - “Dual engine approach” - <i>Gilles Vassal, ACCELERATE</i>
10:20 - 11:00	ACKNOWLEDGING TODAY’S REALITY Understanding the global framework for paediatric oncology drug development for the next 5 years <ul style="list-style-type: none"> Global Oncology trends - <i>Murray Aitken, Iqvia Institute (UK)</i> Global economic impact on biopharmaceuticals. Discussion: Potential effects on pediatric cancer research and drug development
11:10- 12:30	Session I - Improving generation of evidence in paediatric oncology drug development <ul style="list-style-type: none"> Use of Real Word Data: SACHA International - <i>Pablo Berlanga, Gustave Roussy (France)</i> Advancing Childhood Cancer Academic-Industry Collaborative Platform - <i>Pamela Kearns, University of Birmingham (UK)</i> ACCELERATE Working group on Patient Reported Outcomes – <i>Franziska Helmberg, Medical University Innsbruck (Germany)</i> Panel Discussion

12:30 - 1:30	<p>Lunch</p> <p>Advocates networking (closed session)</p>
1:30 - 3:30	<p>CALLING FOR A SHIFT</p> <p>Session II - Accelerating the development of specific paediatric oncology products</p> <ul style="list-style-type: none"> • Learning from the development of antiGD2 antibodies for the treatment of neuroblastoma: an academic perspective - <i>Steven DuBois, Dana-Farber Cancer Institute (USA)</i> • Development of Cuprior™ for the treatment of Wilson disease - <i>Naseem Amin/Omar Camille Kamlin, Orphalan (France)</i> • Generating scientific evidence for specific paediatric drug development - The ITCC-LifeArc project - <i>Jan Molenaar, Princess Maxima Center for Paediatric Oncology (The Netherlands)</i> • New European initiatives (Biotech Act, European Innovation Act) • Panel discussion
3:30 - 4:00	<p>Coffee break + group photo</p>
4:00 - 4:45	<p>Paediatric Strategy and Impact Forums</p> <ul style="list-style-type: none"> • Results of the Paediatric Strategy Forum on Antibody Drug - <i>Margaret Macy, Children's Hospital Colorado (USA)</i> • Presentation of the 2026 Paediatric Strategy Forum • Plan for future Forums and workshop – <i>Elizabeth Fox, St Jude Children's Research Hospital (USA)</i>
4:45 - 6:30	<p>Break-out sessions (on site and by zoom)</p> <ul style="list-style-type: none"> • Topic 1: Accelerating paediatric development of adult innovations: how do we get early conduct of studies leading to regulatory approvals? • Topic 2: Developing specific paediatric oncology drugs: what are the gaps in knowledge, barriers and constraints? What are the drivers to get paediatric oncology in Start-up and Biotech companies?
6:30	<p>End of day 1</p>



CHALLENGING THE SYSTEM

Session III - Will the regulatory framework support and incentivize?

8:30 - 10:30

- Update on regulatory changes for paediatric development of adult anticancer drugs in Europe - *Dominik Karres, European Medicines Agency (The Netherlands)*
- Update on regulatory changes for paediatric development of adult anticancer drugs in North America - *Martha Donoghue, Food and Drug Administration, (USA)*
- Changes in the Declaration of Helsinki for vulnerable populations: a paradigm change - *Rieke van der Graaf, MedEthicsEU (The Netherlands)*
- Panel discussion: What role for ACCELERATE in the changing regulatory environment?

10:30 - 11:00

Coffee break

DRIVING TO ACTION

Session IV - Accelerating drug paediatric development of adult innovations

11:00 - 1:00

- Access to drug for investigator supported trials - *Brenda Weigel, St Jude Children's Research Hospital (USA)*
- Cross border access to therapeutic innovations in Europe - *Francisco Bautista Sirvent, Princess Maxima Centrum (The Netherlands)*
- Facilitating access to clinical trials in Canada - *Daniel Morgenstern, Hospital for Sick Children (Canada)*
- **Report from Break Out Session topic 1 and proposing a plan**
Accelerating paediatric development of adult innovations: how do we get early conduct of studies leading to regulatory approvals?

1:00 - 2:00

Lunch

- **Charity Partners of ACCELERATE networking (closed session)**

2:00 - 3:30

Session V - Developing pediatric-specific oncology drugs

- 2 presentations from start-ups /biotech developing a paediatric oncology innovation
- **Report from Break Out Session topic 2**
Developing specific paediatric oncology drugs: what are the gaps in knowledge, barriers and constraints? What are the drivers to get paediatric oncology in Start-up and Biotech companies?

3:30 - 4:15

Session VI - Building the ACCELERATE work plan

Chairs: *Nicole Scobie and Gilles Vassal, ACCELERATE*

4:15 - 4:30

Wrap up

4:30

End of day 2

